(RMD) ResMed - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7611521078

RMD EPS (Earnings per Share)

This chart shows the EPS (Earnings per Share) of RMD over the last 5 years for every Quarter.

RMD Revenue

This chart shows the Revenue of RMD over the last 5 years for every Quarter.

RMD: Sleep, Respiratory, Diagnostic, Monitoring, Management, Software,

ResMed Inc. is a leading global provider of innovative healthcare solutions, specializing in the development, manufacture, and marketing of medical devices and cloud-based software applications for the diagnosis and treatment of respiratory disorders, including sleep apnea. The companys product portfolio includes a range of diagnostic devices, such as ApneaLink Air and NightOwl, as well as therapy management solutions like myAir and AirView, which enable remote monitoring and patient engagement.

ResMeds software solutions, including Brightree, MatrixCare, and HEALTHCAREfirst, cater to a diverse range of healthcare providers, from home medical equipment suppliers to senior living and hospice organizations. The companys out-of-hospital software solutions are designed to streamline clinical workflows, improve patient outcomes, and enhance operational efficiency. With a strong presence in the global healthcare market, ResMed has established a network of distributors and direct sales forces to market its products to sleep clinics, home healthcare dealers, and hospitals.

From a technical analysis perspective, ResMeds stock (RMD) is currently trading at $244.03, slightly below its 20-day simple moving average (SMA) of $245.85. The stock has been oscillating around its 50-day SMA of $230.53 and 200-day SMA of $235.71, indicating a potential bullish trend. With a relatively low average true range (ATR) of 2.20%, the stock is expected to experience moderate volatility. Given the current support and resistance levels, a potential price target for RMD could be around $256, near its 52-week high.

Fundamentally, ResMeds market capitalization stands at approximately $36.4 billion, with a price-to-earnings (P/E) ratio of 27.85 and a forward P/E of 23.81. The companys return on equity (RoE) is a respectable 25.18%. Considering the current valuation multiples and the companys strong financial performance, it is likely that RMD will continue to attract investor interest. Based on the technical and fundamental data, a forecast for RMD could be a potential price appreciation to around $260-$270, representing a 6-10% upside from current levels, driven by the companys continued innovation and growth in the healthcare technology space.

Additional Sources for RMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

RMD Stock Overview

Market Cap in USD 36,648m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception 1995-06-02

RMD Stock Ratings

Growth Rating 28.8
Fundamental 92.4
Dividend Rating 55.5
Rel. Strength 25
Analysts 3.95 of 5
Fair Price Momentum 226.99 USD
Fair Price DCF 168.20 USD

RMD Dividends

Dividend Yield 12m 0.87%
Yield on Cost 5y 1.35%
Annual Growth 5y 5.30%
Payout Consistency 100.0%
Payout Ratio 23.4%

RMD Growth Ratios

Growth Correlation 3m 82.5%
Growth Correlation 12m 36.7%
Growth Correlation 5y 17.2%
CAGR 5y 9.68%
CAGR/Max DD 5y 0.18
Sharpe Ratio 12m 1.06
Alpha 8.54
Beta 0.788
Volatility 26.90%
Current Volume 427.4k
Average Volume 20d 657.8k
What is the price of RMD shares?
As of June 15, 2025, the stock is trading at USD 249.34 with a total of 427,411 shares traded.
Over the past week, the price has changed by -1.13%, over one month by +0.68%, over three months by +13.73% and over the past year by +18.46%.
Is ResMed a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, ResMed (NYSE:RMD) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 92.42 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RMD is around 226.99 USD . This means that RMD is currently overvalued and has a potential downside of -8.96%.
Is RMD a buy, sell or hold?
ResMed has received a consensus analysts rating of 3.95. Therefor, it is recommend to buy RMD.
  • Strong Buy: 8
  • Buy: 4
  • Hold: 6
  • Sell: 0
  • Strong Sell: 1
What are the forecasts for RMD share price target?
According to our own proprietary Forecast Model, RMD ResMed will be worth about 258.3 in June 2026. The stock is currently trading at 249.34. This means that the stock has a potential upside of +3.58%.
Issuer Target Up/Down from current
Wallstreet Target Price 264.5 6.1%
Analysts Target Price 264.5 6.1%
ValueRay Target Price 258.3 3.6%